EcoDrugPlus

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSPKIG00000024064
Gene Symbol: KCNJ5
4 Cross references
134 Possible Orthologues:

Potassium Large Conductance Calcium-Activated Channel, Subfamily M, Alpha Member 1a

Ensembl ID : ENSPKIG00000011330
Gene Symbol: KCNMA1A
1 Cross references
235 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSPKIG00000005192
Gene Symbol: KCNK2
3 Cross references
152 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 3

Ensembl ID : ENSPKIG00000021013
Gene Symbol: KCNK3
3 Cross references
202 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 9

Ensembl ID : ENSPKIG00000002180
Gene Symbol: KCNK9
3 Cross references
218 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSPKIG00000024025
Gene Symbol: KCNA5
3 Cross references
169 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSPKIG00000017074
Gene Symbol: KCND3
4 Cross references
192 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3-Like

Ensembl ID : ENSPKIG00000020130
Gene Symbol: LOC111851101
3 Cross references
193 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSPKIG00000009282
Gene Symbol: KCNH2
4 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Kqt Member 2-Like

Ensembl ID : ENSPKIG00000012195
Gene Symbol: LOC111855832
3 Cross references
246 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSPKIG00000006203
Gene Symbol: KCNQ2
4 Cross references
246 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSPKIG00000007283
Gene Symbol: KCNQ3
3 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).